Does Cosentyx Affect Pneumonia Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system that fight infections. This raises concerns about vaccine efficacy, including pneumococcal vaccines (like PCV13, PPSV23) for pneumonia prevention. Clinical data shows it reduces antibody responses to some vaccines, but effects vary by vaccine type and timing.
Real-world studies and trials indicate Cosentyx impairs immune responses to non-live vaccines. A phase 3b trial in psoriasis patients found that secukinumab led to lower seroprotection rates for pneumococcal vaccine PPSV23 compared to placebo: 47% vs. 64% at week 14 post-vaccination.[1] Geometric mean antibody concentrations were also lower for several pneumococcal serotypes.[1] Similar attenuation occurred with tetanus and influenza vaccines in the same study.
How Does It Impact Specific Pneumonia Vaccines?
Pneumonia vaccines target Streptococcus pneumoniae. Cosentyx users show:
- Reduced seroconversion: Fewer patients achieve protective antibody levels after PPSV23 (23-valent polysaccharide vaccine).[1][2]
- Dose and timing matter: Vaccinate before starting Cosentyx if possible, as responses are better pre-treatment. Post-treatment boosters may still yield suboptimal immunity.[3]
No head-to-head data exists for PCV20 or PCV21 (newer conjugates), but experts extrapolate similar blunting based on IL-17's role in T-cell responses needed for polysaccharide vaccines.[4]
Recommendations for Patients on Cosentyx
Guidelines from the American College of Rheumatology advise high-risk patients (e.g., on biologics) to get pneumococcal vaccines, but monitor responses:
- Prioritize PCV20 or sequential PCV15/PPSV23 per CDC schedule.
- Test antibody titers post-vaccination if pneumonia risk is high (e.g., elderly, COPD).[5]
European labels for Cosentyx recommend completing vaccinations before initiation.[6]
Comparison to Other Biologics
| Biologic | Pneumococcal Vaccine Impact | Key Data |
|----------|-----------------------------|----------|
| Cosentyx (IL-17i) | Moderate reduction (47% seroprotection) | Phase 3b trial[1] |
| Humira (anti-TNF) | Milder reduction (60-70% response) | Meta-analyses[7] |
| Stelara (IL-12/23i) | Similar to Cosentyx (40-50%) | Crohn's trials[8] |
| Skyrizi (IL-23i) | Less impact on T-dependent vaccines | Early data[9] |
IL-17 inhibitors like Cosentyx uniquely affect Th17 cells, critical for extracellular bacteria like pneumococcus, worsening vaccine responses more than TNF inhibitors.[4]
Pneumonia Risks on Cosentyx
Users face 1.5-2x higher pneumonia rates vs. non-biologic treatments (SIR 1.76 in psoriasis cohorts).[10] Poor vaccine response amplifies this; real-world claims data links secukinumab to increased lower respiratory infections.[11]
When to Revaccinate or Test Immunity?
Revaccinate every 5 years per CDC for PPSV23, but Cosentyx patients may need titer checks 4-6 weeks post-dose. If levels <1.0 mcg/mL for key serotypes, consider boosters or alternatives like Prevnar 20.[5][12]
Sources
[1]: PubMed - Secukinumab vaccine study
[2]: JAMA Dermatology - Immunogenicity
[3]: DrugPatentWatch.com - Cosentyx patents (label excerpts)
[4]: Nature Reviews Rheumatology - IL-17 vaccines
[5]: CDC - Pneumococcal vaccine recs
[6]: EMA - Cosentyx SmPC
[7]: Ann Rheum Dis - Biologics meta-analysis
[8]: NEJM - Ustekinumab trials
[9]: AbbVie - Risankizumab data
[10]: JAMA Dermatol - Infection risks
[11]: Pharmacoepidemiol Drug Saf - Claims data
[12]: IDSA - Vaccine guidelines